Selected financial information for N7 Tactical Solutions is provided in the table below. N7 is currently all equity financed, but it is considering a leveraged capital structure, details of which are presented in the column labeled "Proposed."
Assume that N7 generates perpetual annual EBIT. Assume that all cash flows occur at the end of the year and we are currently at the beginning of a year. Assume that taxes are zero. Assume that all of net income is paid out as a dividend. Assume that the debt is perpetual with annual coupons (and yield) of 3%.
If N7 recapitalizes, it will use the borrowed funds to repurchase (and cancel) shares. Determine both the value of the company and the value of the company's equity if it recapitalizes.
| | Capital Structure | Capital Structure |
| | Current | Proposed |
| EBIT | $150,000 | $150,000 |
| Debt, D | $0 | $900,000 |
| Cost of Debt, kd | | 3% |
| Cost of Equity | 5% | |
◦ Company value: $3,000,000; Equity value: $2,100,000
◦ Company value: $3,000,000; Equity value: $3,000,000
◦ Company value: $2,100,000; Equity value: $2,100,000
◦ Company value: $3,000,000; Equity value: $3,900,000
◦ Company value: $5,000,000; Equity value: $4,100,000
Selected Androgens and Anabolic Steroids
Bone Resorption Inhibitors and Selected Drugs
Selected Neurotransmitters: Effects and Clinical Applications
Selected Drugs for Osteoporosis and Other Bone Disorders
table
Short Table of Laplace Tranforms